Beijing SL Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Beijing SL Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥66.55 Million ≈ $9.74 Million USD) by net assets (CN¥5.70 Billion ≈ $834.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Beijing SL Pharmaceutical Co Ltd (2003–2025)
Cash flow conversion efficiency of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. This chart illustrates how Beijing SL Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Beijing SL Pharmaceutical Co Ltd for real-time trading data and today's change.
Beijing SL Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Beijing SL Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Beijing SL Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see how much is Beijing SL Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Salfacorp
SN:SALFACORP
|
0.122x |
|
Metro Investment Development Co Ltd
SHG:600683
|
-0.022x |
|
Dongfeng Electronic Technology Co Ltd
SHG:600081
|
0.063x |
|
MBK Public Company Limited
BK:MBK-R
|
0.028x |
|
Yijiahe Technology Co Ltd
SHG:603666
|
-0.030x |
|
Bloomin Brands Inc
NASDAQ:BLMN
|
0.209x |
|
Eos Energy Enterprises Inc
NASDAQ:EOSE
|
0.229x |
|
Infund Holding Co Ltd
SHE:002141
|
0.075x |
Annual Cash Flow Conversion Efficiency for Beijing SL Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. Review Beijing SL Pharmaceutical Co Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.19 Billion ≈ $759.25 Million |
CN¥257.66 Million ≈ $37.70 Million |
0.050x | +22.90% |
| 2024-12-31 | CN¥5.58 Billion ≈ $816.62 Million |
CN¥225.49 Million ≈ $33.00 Million |
0.040x | -48.99% |
| 2023-12-31 | CN¥5.81 Billion ≈ $850.19 Million |
CN¥460.20 Million ≈ $67.34 Million |
0.079x | +11.33% |
| 2022-12-31 | CN¥5.48 Billion ≈ $801.78 Million |
CN¥389.82 Million ≈ $57.04 Million |
0.071x | -18.44% |
| 2021-12-31 | CN¥5.33 Billion ≈ $779.39 Million |
CN¥464.63 Million ≈ $67.99 Million |
0.087x | +4.57% |
| 2020-12-31 | CN¥4.98 Billion ≈ $729.42 Million |
CN¥415.84 Million ≈ $60.85 Million |
0.083x | -39.59% |
| 2019-12-31 | CN¥4.82 Billion ≈ $705.49 Million |
CN¥665.83 Million ≈ $97.43 Million |
0.138x | +28.62% |
| 2018-12-31 | CN¥4.52 Billion ≈ $661.20 Million |
CN¥485.17 Million ≈ $71.00 Million |
0.107x | +21.25% |
| 2017-12-31 | CN¥4.30 Billion ≈ $629.14 Million |
CN¥380.72 Million ≈ $55.71 Million |
0.089x | -12.31% |
| 2016-12-31 | CN¥3.93 Billion ≈ $575.09 Million |
CN¥396.86 Million ≈ $58.07 Million |
0.101x | -27.73% |
| 2015-12-31 | CN¥3.61 Billion ≈ $528.73 Million |
CN¥504.87 Million ≈ $73.88 Million |
0.140x | -4.41% |
| 2014-12-31 | CN¥3.18 Billion ≈ $465.50 Million |
CN¥465.00 Million ≈ $68.04 Million |
0.146x | +8.93% |
| 2013-12-31 | CN¥2.59 Billion ≈ $378.85 Million |
CN¥347.41 Million ≈ $50.84 Million |
0.134x | -28.91% |
| 2012-12-31 | CN¥2.11 Billion ≈ $308.98 Million |
CN¥398.60 Million ≈ $58.33 Million |
0.189x | +39.20% |
| 2011-12-31 | CN¥1.69 Billion ≈ $246.66 Million |
CN¥228.59 Million ≈ $33.45 Million |
0.136x | -31.02% |
| 2010-12-31 | CN¥1.21 Billion ≈ $177.26 Million |
CN¥238.13 Million ≈ $34.85 Million |
0.197x | +10.81% |
| 2009-12-31 | CN¥983.06 Million ≈ $143.85 Million |
CN¥174.41 Million ≈ $25.52 Million |
0.177x | -30.38% |
| 2008-12-31 | CN¥762.61 Million ≈ $111.59 Million |
CN¥194.32 Million ≈ $28.44 Million |
0.255x | +59.16% |
| 2007-12-31 | CN¥551.93 Million ≈ $80.76 Million |
CN¥88.36 Million ≈ $12.93 Million |
0.160x | +18.56% |
| 2006-12-31 | CN¥426.20 Million ≈ $62.37 Million |
CN¥57.55 Million ≈ $8.42 Million |
0.135x | +8.78% |
| 2005-12-31 | CN¥382.49 Million ≈ $55.97 Million |
CN¥47.48 Million ≈ $6.95 Million |
0.124x | +43.52% |
| 2004-12-31 | CN¥361.45 Million ≈ $52.89 Million |
CN¥31.26 Million ≈ $4.57 Million |
0.086x | -67.43% |
| 2003-12-31 | CN¥115.05 Million ≈ $16.84 Million |
CN¥30.55 Million ≈ $4.47 Million |
0.266x | -- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothec… Read more